Related Experiment Video
Updated: Jun 5, 2025

09:47
Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
954
Adaptive Subtype and Stage Inference for Alzheimer's Disease
Xinkai Wang1,2, Yonggang Shi1,2
1Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California (USC), Los Angeles, CA 90033, USA.
Summary
This study introduces an adaptive algorithm to improve subtype and stage inference for progressive disorders. The new method learns subtype-specific disease progression events, enhancing understanding of disease heterogeneity.
Area of Science:
- Computational biology
- Biomedical data analysis
- Disease progression modeling
Background:
- Event-based models like Subtype and Stage Inference (SuStaIn) capture temporal and phenotypical patterns in progressive disorders.
- Existing models struggle with subtypes exhibiting different progression rates and fixed prior events.
- Understanding disease heterogeneity is crucial for effective treatment strategies.
Purpose of the Study:
- To develop an adaptive algorithm for learning subtype-specific events.
- To enhance subtype and stage inference in progressive diseases.
- To address limitations of current event-based models in capturing variable progression rates.
Main Methods:
- Proposed an adaptive algorithm for joint learning of subtype-specific events and inference.
- Utilized simulation studies to evaluate the algorithm's performance.
- Applied the algorithm to Alzheimer's Disease (AD) data.
Main Results:
- The adaptive algorithm demonstrated improved performance across various metrics in simulations.
- Successfully identified different levels of biomarker abnormality within distinct subtypes of Alzheimer's Disease.
- The method effectively captures disease heterogeneity and progression dynamics.
Conclusions:
- The proposed adaptive algorithm enhances subtype and stage inference for progressive disorders.
- This approach offers a more nuanced understanding of disease heterogeneity and progression.
- Effective for analyzing complex diseases like Alzheimer's Disease with biomarker data.
Related Concept Videos
Alzheimer's Disease: Overview
447
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
447
Alzheimer's Disease: Treatment
163
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
163

